Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition
暂无分享,去创建一个
J. Espinosa | M. Galbraith | Keith P. Smith | Kelly D. Sullivan | Katherine A. Waugh | B. Enriquez-Estrada | A. Rachubinski | Elena W Y Hsieh | Paula Araya | K. Worek | Michael P Ludwig | Kohl T. Kinning | Ross E. Granrath | Neetha Paul Eduthan
[1] J. Espinosa,et al. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model , 2023, Nature Genetics.
[2] J. Espinosa,et al. IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome , 2022, Cell reports.
[3] C. Stephani,et al. Janus kinase inhibitors for the treatment of COVID-19. , 2022, The Cochrane database of systematic reviews.
[4] Faisal A. Almalki,et al. A Comprehensive Overview of Globally Approved JAK Inhibitors , 2022, Pharmaceutics.
[5] Randall W. Grout,et al. Health Supervision for Children and Adolescents With Down Syndrome. , 2022, Pediatrics.
[6] Ryan M. Baxter,et al. Specialized interferon action in COVID-19 , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[7] E. Head,et al. Type I Interferon Signaling Drives Microglial Dysfunction and Senescence in Human iPSC Models of Down Syndrome and Alzheimer’s Disease , 2021, bioRxiv.
[8] M. Rafii,et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder , 2021, Journal of neurodevelopmental disorders.
[9] Ryan M. Baxter,et al. The COVIDome Explorer researcher portal , 2021, Cell Reports.
[10] L. Malle,et al. Down syndrome and type I interferon: not so simple. , 2021, Current opinion in immunology.
[11] T. Kang,et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics , 2021, International journal of molecular sciences.
[12] J. Espinosa,et al. JAK inhibition for treatment of psoriatic arthritis in Down syndrome , 2021, Rheumatology.
[13] M. Mayer,et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey , 2021, EClinicalMedicine.
[14] D. Lio,et al. Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes , 2020, Genes.
[15] J. Espinosa,et al. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. , 2020, Cell reports.
[16] B. Chicoine,et al. Medical Care of Adults With Down Syndrome: A Clinical Guideline. , 2020, JAMA.
[17] D. Chaussabel,et al. Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome , 2020, Journal of Clinical Immunology.
[18] Patrick J. Lao,et al. Further understanding the connection between Alzheimer's disease and Down syndrome , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[19] A. Iwasaki,et al. Contributions of maternal and fetal antiviral immunity in congenital disease , 2020, Science.
[20] J. Espinosa. Down Syndrome and COVID-19: A Perfect Storm? , 2020, Cell Reports Medicine.
[21] S. Antonarakis,et al. Down syndrome , 2020, Nature Reviews Disease Primers.
[22] David S. Wishart,et al. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.
[23] J. Espinosa,et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity , 2019, Proceedings of the National Academy of Sciences.
[24] Rani K. Powers,et al. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors , 2019, Nature Communications.
[25] S. Ziegler,et al. TSLP: from allergy to cancer , 2019, Nature Immunology.
[26] Jennifer A. McWilliams,et al. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. , 2019, Cell reports.
[27] C. Dunnick,et al. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata , 2019, JAAD case reports.
[28] J. Pennings,et al. Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model , 2018, bioRxiv.
[29] M. Gerosa,et al. The use of biologics and small molecules in pregnant patients with rheumatic diseases , 2018, Expert review of clinical pharmacology.
[30] A. Iwasaki,et al. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. , 2018, Immunity.
[31] S. Feldman,et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis , 2018, Inflammatory bowel diseases.
[32] J. Pennings,et al. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome , 2018, Disease Models & Mechanisms.
[33] Mark D. Robinson,et al. Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.
[34] A. D’Alessandro,et al. Red blood cell metabolism in Down syndrome: hints on metabolic derangements in aging. , 2017, Blood advances.
[35] J. O’Shea,et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.
[36] Ahwan Pandey,et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation , 2017, Scientific Reports.
[37] Xiaoyan Qin,et al. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis , 2017, Oncotarget.
[38] Y. Crow,et al. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.
[39] B. Skotko,et al. Estimation of the number of people with Down syndrome in the United States , 2016, Genetics in Medicine.
[40] Virginia Pascual,et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.
[41] Jørgen H Olsen,et al. Low risk of solid tumors in persons with Down syndrome , 2016, Genetics in Medicine.
[42] R. Fischer-Betz,et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.
[43] Piet Demeester,et al. FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[44] Eli R. Zunder,et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.
[45] H. Lähdesmäki,et al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. , 2015, Human molecular genetics.
[46] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[47] P. Adlard,et al. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease , 2014, Neurobiology of Aging.
[48] Sean C. Bendall,et al. Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[49] D. Munn,et al. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.
[50] Larry Gold,et al. Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.
[51] V. Pascual,et al. The interferon-α signature of systemic lupus erythematosus , 2010, Lupus.
[52] A. Sher,et al. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation , 2010, Mucosal Immunology.
[53] W. Bowers,et al. Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. , 2009, The American journal of pathology.
[54] Robert Gentleman,et al. flowCore: a Bioconductor package for high throughput flow cytometry , 2009, BMC Bioinformatics.
[55] N. Nowak,et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. , 2007, Human molecular genetics.
[56] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[57] Y. Tomer,et al. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. , 2004, Autoimmunity reviews.
[58] M. Hattori,et al. The DNA sequence of human chromosome 21 , 2000, Nature.
[59] T. Heffernan,et al. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[60] L. Maroun. Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. , 1995, Teratology.
[61] L. Maroun. Interferon effect on ribosomal ribonucleic acid related to chromosome 21 ploidy. , 1979, The Biochemical journal.
[62] C. Epstein,et al. Human Chromosome 21 Dosage: Effect on the Expression of the Interferon Induced Antiviral State , 1974, Science.
[63] J. Lejeune,et al. [Human chromosomes in tissue cultures]. , 1959, Comptes rendus hebdomadaires des seances de l'Academie des sciences.
[64] E BOYLAND,et al. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. , 1956, The Biochemical journal.
[65] A. Rzhetsky,et al. Prevalence of Common Disease Conditions in a Large Cohort of Individuals With Down Syndrome in the United States. , 2021, Journal of patient-centered research and reviews.
[66] A. Rosen,et al. Type I interferons: crucial participants in disease amplification in autoimmunity , 2010, Nature Reviews Rheumatology.
[67] C. Epstein,et al. Abnormalities in the interferon response and immune systems in Down syndrome: studies in human trisomy 21 and mouse trisomy 16. , 1987, Progress in clinical and biological research.
[68] C. Epstein,et al. Synthesis of interferon-induced polypeptides in normal and chromosome 21-aneuploid human fibroblasts: relationship to relative sensitivities in antiviral assays. , 1980, Journal of interferon research.